Michael Luu
Overview
Explore the profile of Michael Luu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
801
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen M, Luu M, Sacks W, Orloff L, Wallner L, Mallen-St Clair J, et al.
Lancet Diabetes Endocrinol
. 2025 Feb;
13(3):188-195.
PMID: 39922210
Background: In the USA, the incidence of thyroid cancer increased rapidly for several decades, although some studies have suggested that it has now plateaued or even begun to decrease. We...
2.
Heard J, Masterson J, Luu M, Gale R, Spiegel B, Freedland S, et al.
Urol Oncol
. 2024 Dec;
PMID: 39674764
Background: Guidelines for prostate cancer treatment in men with limited life expectancy are based on expert opinion. Patient preferences for when to defer treatment based on longevity are unknown. We...
3.
Daskivich T, Luu M, Heard J, Thomas I, Leppert J
JAMA Intern Med
. 2024 Nov;
185(1):28-36.
PMID: 39527047
Importance: Men with limited life expectancy (LE) have historically been overtreated for prostate cancer despite clear guideline recommendations. With increasing use of active surveillance, it is unclear if overtreatment of...
4.
Kaur B, Yeo Y, Liang J, Luu M, Ayoub W, Kuo A, et al.
Gastro Hep Adv
. 2024 Aug;
3(2):230-237.
PMID: 39129956
Background And Aims: The change in hepatocellular carcinoma (HCC) care continuum during the coronavirus disease 2019 (COVID-19) pandemic remains unknown at a national level in the United States. We sought...
5.
Bastien A, Amin L, Vasquez M, Cong I, Luu M, Laszlo M, et al.
Head Neck
. 2024 Jul;
47(1):139-149.
PMID: 39077966
Background: As a surrogate of malnutrition, degree of weight loss and recovery from head and neck cancer (HNC) treatment is understudied. The influence of modifiable factors that affect weight, including...
6.
Luu M, Gresham G, Henry L, Kim S, Rogatko A, Yothers G, et al.
JCO Clin Cancer Inform
. 2024 Jul;
8:e2400007.
PMID: 39013121
Purpose: Longitudinal patient tolerability data collected as part of randomized controlled trials are often summarized in a way that loses information and does not capture the treatment experience. To address...
7.
Bastien A, Ng J, Cong I, Garcia J, Walgama E, Luu M, et al.
Oral Oncol
. 2024 Jun;
156:106894.
PMID: 38909394
Objective: Circulating tumor DNA assays have robust potential as molecular surveillance tools. They may also exacerbate patient distress without improving outcomes. We investigate patient acceptability of a validated ctHPVDNA assay...
8.
Dallmer J, Luu M, Saouaf R, Spiegel B, Freedland S, Daskivich T
J Am Coll Radiol
. 2024 Jun;
21(10):1634-1642.
PMID: 38880288
Introduction: Prostate MRI reports use standardized language to describe risk of clinically significant prostate cancer (csPCa) from "equivocal" (Prostate Imaging Reporting and Data System [PI-RADS] 3), "likely" (PI-RADS 4), to...
9.
Liang J, Lee Y, Yeo Y, Luu M, Ayoub W, Kuo A, et al.
Clin Transl Gastroenterol
. 2024 Jun;
15(7):e00723.
PMID: 38829967
Introduction: Access to hepatocellular carcinoma (HCC) surveillance and treatments were disrupted during the coronavirus disease 2019 (COVID-19) pandemic. We aimed to characterize the impact of the pandemic on HCC incidence...
10.
Friedrich N, Luu M, Gale R, Chaplin A, Ballas L, Sandler H, et al.
Urol Oncol
. 2024 May;
42(9):288.e7-288.e15.
PMID: 38762384
Introduction: Multidisciplinary consultations improve decisional conflict and guideline-concordant treatment for men with prostate cancer (PC), but differences in the content discussed by specialty during consultations are unknown. Methods: We audiorecorded...